In the last week, Japan and India have also recommended approval of Merck’s experimental pill, which has already been approved in Britain, Denmark and the Philippines, among others, while South Korea on Monday authorised Pfizer’s treatment for emergency use.
Merck has signed deals to sell about nine million courses of its treatment to governments around the world, but on Dec 22 France became the first country to publicly say it had cancelled its order following disappointing trial data. It hopes instead to receive Pfizer’s drug before the end of January.
In the European Union, both treatments are under review by the European Medicines Agency (EMA), though the regulator has said they can be used in adults ahead of any wider recommendation.
|
Merck |
|
|
|
|
COUNTRY |
VOLUME |
PRICE |
TIMING OF SOURCE DELIVERY
|
|
Australia |
300,000 doses |
|
|
|
Belgium |
10,000 doses |
|
|
|
Canada |
500,000 courses |
|
|
|
Indonesia |
600,000 – 1 million doses |
|
December |
|
Italy |
50,000 courses |
|
|
|
Japan |
1.6 million courses |
1.2 billion |
|
|
Malaysia |
150,000 courses |
|
|
|
Philippines |
300,000 courses |
100-150 pesos ($1.97-$2.96) per |
November 2024 |
|
South Korea |
200,000 courses |
|
|
|
Switzerland |
8,640 doses |
|
Jan 2024 “at the latest” |
|
Thailand |
200,000 courses |
|
|
|
UK |
2,230,000 courses |
|
Early 2024 |
|
United States |
3,100,000 courses |
$700 per course, total of $2.2 |
|
|
EU |
|
|
|
|
Germany |
|
|
|
|
Pfizer pill |
|
|
|
|
COUNTRY |
VOLUME |
PRICE |
TIMING OF DELIVERY
|
|
Australia |
500,000 courses |
|
|
|
Canada |
1 million doses |
|
|
|
Israel |
100,000 |
|
|
|
Italy |
50,000 courses |
|
|
|
South Korea |
70,000 course |
|
|
|
UK |
2,750,000 courses |
|
Early 2024 |
|
United States |
10,000,000 courses |
$530 per course, total of $5.29 |
by the end of 2024 |
|
Thailand |
|
|
|
|
EU |
|
|
|
|
Germany |
|
|
|
